A federal courtroom dominated towards a California-based diagnostic laboratory in its newest try to safe Medicare protection for 2 of its breast most cancers checks after reimbursement was denied by a Medicare contractor for lack of scientific utility.
In an opinion issued July 26, the US District Court docket for the District of Columbia upheld Medicare’s denial of protection for Agendia Inc.’s BluePrint and TargetPrint checks, that are used to detect breast most cancers and information therapy choices.
The corporate had argued that the “substantial deference” given to native protection determinations, which permit non-public corporations to find out whether or not a service or merchandise qualifies …
